AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$RNA

Atrium Therapeutics, Inc.

Price · $RNAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $RNA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $RNA in the last 30 days.

Top stories · $RNAMore →
FEB 27·PR NewswireMed

Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform

Avidity Biosciences announced the expansion of its RNA therapeutic discovery pipeline, adding new research and development candidates in skeletal muscle and cardiology. The company is leveraging its proprietary AOC platform to target previously untreatable diseases and continues to advance three rare disease programs in Phase 1/2 clinical development for myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Avidity also maintains collaborations with Eli Lilly and Company and MyoKardia to further explore its AOC platform's potential.

JAN 22·Investing.com

Avidity Biosciences stock hits all-time high at $72.70

Avidity Biosciences Inc. reached an all-time high of $72.70, marking a 141.25% increase over the past year, driven by investor confidence in its RNA-based therapies. The company also announced a Managed Access Program for delpacibart zotadirsen for Duchenne muscular dystrophy patients and will be acquired by Novartis for approximately $12 billion ($72 per share). Following the acquisition news, analysts at Chardan Capital Markets and TD Cowen downgraded the stock and adjusted their price targets.

DEC 19·MarketBeat

Avidity Biosciences (NASDAQ:RNA) Lowered to Hold Rating by Evercore ISI

Avidity Biosciences (NASDAQ:RNA) has been downgraded to a "Hold" rating by Evercore ISI, with other firms also cutting ratings, resulting in a consensus "Hold" with an average price target of $69.57. The company missed Q3 EPS estimates, reporting ($1.27) against ($1.05) expected, despite a 420.8% revenue jump to $12.48M. Insiders have also sold approximately $1.5 million worth of shares recently, and the stock is trading near its one-year high.

News on $RNA

All news →